SOLA Biosciences
sola-bio.com
Actively hiring
Cell & Gene Therapy
Bioinformatics
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
UTEC
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 14, 2025
Launched SOLA Biosciences Launches Japanese Subsidiary in Tokyo · sola-bio.com
Backed byfrom the funds' portfolios and accelerator catalogs
UTEC Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
MediSix Therapeutics develops innovative T-cell therapies using its proprietary PEBL technology platform. An IASO Biotechnology subsidiary.
Invest in cutting-edge immunotherapy solutions targeting cancers and rheumatic diseases.
Redefining Complement Therapies. Complement Therapeutics is a clinical-stage biotechnology company advancing precision therapies for…
Spatial proteomics from H&E. Lattice predicts spatially resolved protein-marker maps from routine H&E, delivered as virtual mIF channels.
Discover 64xBio's end-to-end platform for next-generation biologics. We enable scalable therapeutic systems through VectorSelect™…
Immunotherapiesfor fibrotic disease. Neotis is designing therapies that direct the immune system to eliminate cells driving fibrotic…
Overview
SOLA Biosciences develops JUMP70 platform therapies targeting protein misfolding in ALS, Parkinson’s, and other conformational diseases.
News
合同会社SOLA Biosciences Japan、AMED「創薬ベンチャーエコシステム強化事業」に採択
合同会社SOLA Biosciences Japan、AMED「創薬ベンチャーエコシステム強化事業」に採択 The post 合同会社SOLA Biosciences Japan、AMED「創薬ベンチャーエコシステム強化事業」に採択 appeared first on SOLA BIOSCIENCES.
Read more
Report
SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients
SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients The post SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP
Read more
Report
合同会社SOLA Biosciences Japan、AMED「創薬ベンチャーエコシステム強化事業」に採択 PRワイヤー
ALSの病因タンパク質TDP-43の構造と機能の回復を目指す遺伝子治療SOL-257の開発を推進2026年9月28日合同会社SOLA Biosciences JapanSOLA Biosciences Inc.米国ボストンに本社を置くSOLA Biosciences Inc.の完全子会社である合同会社SOLA Biosciences Japan本社：東京都、以下「SOLA Japan」SOLA Biosciences Inc.と合わせて「SOLA」は、国立研究開発法人日本医療研究開発機構AMEDの「創薬ベ
Read more
Report
SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients
/PRNewswire/ -- SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"),...
Read more
Report
「創薬ベンチャーエコシステム強化事業創薬ベンチャー公募」第12回採択決定
国立研究開発法人日本医療研究開発機構AMEDでは、「創薬ベンチャーエコシステム強化事業創薬ベンチャー公募」の公募第12回について、課題評価委員会 における厳正な審査を行った結果、合同会社SOLA Biosciences Japanによる研究開発課題の採択を決定 The post 「創薬ベンチャーエコシステム強化事業創薬ベンチャー公募」第12回採択決定 appeared first on SOLA BIOSCIENCES.
Read more
Report
Report
Featured in podcast: Tech Startup の舞台裏 by UTEC
Featured in podcast: Tech Startup の舞台裏 by UTEC #35 SOLA Biosciences: 後編 which showcases the passion of University of Tokyo Edge Capital Partners (UTEC)-a venture capital firm that focuses on investing in the deep-tech sector-and the startups in which it i
Read more
Report
Featured in Nikkei Biotechnology & Business, a leading Japan-based, industry-focused biotech news and analysis publication
Featured in Nikkei Biotechnology & Business, a leading Japan-based, industry-focused biotech news and analysis publication.SOLA Biosciences 社、フォールディング異常蛋白質に作用する遺伝子治療薬を開発 The post Featured in Nikkei Biotechnology & Business, a leading Japan-based, industry
Read more
Report
Featured in podcast: Tech Startup の舞台裏 by UTEC
Featured in podcast: Tech Startup の舞台裏 by UTEC #34 SOLA Biosciences: 後編 which showcases the passion of University of Tokyo Edge Capital Partners (UTEC)-a venture capital firm that focuses on investing in the deep-tech sector-and the startups in which it i
Read more
Report
SOLA Biosciences Launches Japanese Subsidiary in Tokyo
SOLA Biosciences Launches Japanese Subsidiary in Tokyo合同会社SOLA Biosciences JAPANSOLA Biosciences Japan, GK本部: 103-0023東京都中央区日本橋本町2丁目3番11号日本橋ライフサイエンスビルディングNihonbashi LifeScience Building2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023 The post SOLA Biosci
Read more
Report
Show more news